Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02315586 |
|
Recruitment Status :
Recruiting
First Posted : December 12, 2014
Last Update Posted : July 26, 2019
|
Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Background:
- Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers want to study the disease and learn new ways to treat it.
Objectives:
- To discover new pathways that are involved in pulmonary fibrosis. To develop new drugs that may be used to treat pulmonary fibrosis.
Eligibility:
- People at least 18 years old with IPF.
- Healthy volunteers at least 18 years old.
Design:
- Participants will be screened with medical history, questionnaire, and physical exam. They will have blood, lung, and walking tests and chest scans.
- All participants will have 1 study visit, including:
- Medical history and physical exam.
- Questions about their breathing.
- Blood tests.
- Breathing tests.
- Six-minute walk test.
- Pregnancy test.
- Chest x-ray (healthy volunteers) or chest CT scan (people with pulmonary fibrosis ).
- Small area of skin may be removed.
- Genetic tests of blood and skin samples. Participants will probably not be informed of any findings. Samples may be used to make stem cells for use in research. Participants may be contacted in the future to give consent for this research.
- Some participants will have repeat visits over many years, repeating many of the study tests.
| Condition or disease |
|---|
| Idiopathic Pulmonary Fibrosis |
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective treatments for patients with IPF. Levels of apolipoprotein A-I (apoA-I) have been found to be reduced in the lungs of patients with IPF, while administration of human apoA-I has been shown to reduce bleomycin-induced collagen deposition in a murine model. Here, we would like to assess whether apoA-I pathways modify lung cell biology in patients with IPF. This is a specimen procurement, clinical phenotyping and genotyping protocol that will assess whether holo-apoA-I and apolipoprotein A-I mimetic peptides, can attenuate key pathogenic manifestations of IPF, such as proliferation and extracellular matrix generation by pulmonary fibroblasts, which may serve as evidence to support future human clinical trials of apoA-I for the treatment of IPF. Furthermore, the identification of new apoA-I responsive genes and pathways that mediate fibroblast proliferation in IPF may provide insights into disease pathogenesis and identify new therapeutic targets. Lastly, if induced pluripotent stem (iPS) cells can be successfully shown to model responsiveness of lung cells to apoA-I therapy, then this approach may be expanded with the goal of providing a personalized medicine analysis that could in the future guide selection of the most effective therapy for individual patients.
| Study Type : | Observational |
| Estimated Enrollment : | 500 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Cross-Sectional |
| Official Title: | Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis |
| Actual Study Start Date : | January 28, 2015 |
| Estimated Primary Completion Date : | December 31, 2029 |
| Estimated Study Completion Date : | December 31, 2029 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Idiopathic pulmonary fibrosis
MedlinePlus related topics:
Pulmonary Fibrosis
Primary Outcome Measures :
- Specimen procurement, clinical phenotyping and genotyping that will assess whether holo-apoA-I and apolipoprotein A-I mimetic peptides, can attenuate key pathogenic manifestations of IPF [ Time Frame: 5 years ]Therefore, we request participation of a maximum of 500 subjects (250 IPF patients and 250 non-IPF subjects) to ensure that we have a sufficient number of samples to achieve the goals of the study.
Secondary Outcome Measures :
- The effects of stimulating cultures of primary pulmonary fibroblasts from IPF patients and subjects without IPF with apolipoprotein A-I will also be compared to the effects seen following stimulation with apolipoprotein E [ Time Frame: 5 years ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Participants will be enrolled at the NIH Clinical Center. IPF subjects will be recruited from the INOVA Fairfax Advanced Lung Disease Program and study procedures will be performed in the outpatient unit/day hospital at the NIH Clinical Center.@@@
Criteria
- INCLUSION CRITERIA:
Patient:
Males and females over the age of 18 with a diagnosis of IPF.
EXCLUSION CRITERIA:
Patient:
Female subjects who are pregnant or lactating
INCLUSION CRITERIA:
Normal Volunteer:
Males and females over the age of 18 without IPF.
EXCLUSION CRITERIA:
Normal Volunteer:
Female subjects who are pregnant or lactating
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02315586
Contacts
| Contact: Maryann M Kaler, C.R.N.P. | (301) 451-5916 | mk371e@nih.gov | |
| Contact: Stewart J Levine, M.D. | (301) 402-1553 | levines@nhlbi.nih.gov |
Locations
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov | |
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
| Principal Investigator: | Stewart J Levine, M.D. | National Heart, Lung, and Blood Institute (NHLBI) |
Additional Information:
| Responsible Party: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT02315586 History of Changes |
| Other Study ID Numbers: |
150017 15-H-0017 |
| First Posted: | December 12, 2014 Key Record Dates |
| Last Update Posted: | July 26, 2019 |
| Last Verified: | July 23, 2019 |
| Studies a U.S. FDA-regulated Drug Product: | No | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):
|
Idiopathic Pulmonary Fibrosis Apoliprotein A-1 |
Additional relevant MeSH terms:
|
Fibrosis Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Idiopathic Interstitial Pneumonias |
Pathologic Processes Lung Diseases Respiratory Tract Diseases Lung Diseases, Interstitial |